In 2006, having gone public in 1988 only a year of two after becoming SBIR involved but graduating out of the program in 2004, NeoRx Corporation changed name to Poniard Pharmaceuticals, Inc (NASDAQ:PARD). The firm raised major amounts of capital both before and after going public and had working relations of ocnsequence with almost every corporate and academic entity in the space. An effort was made unsuccessfuly to achieve a reverse merger with Allozyne in 2011. For a while trading as Poniard Pharmaceuticals Inc (PARD:OTC Pink, in 2014, Verastem Inc. (cancer stem cell-targeting therapies) licensed all rights to focal adhesion kinase (FAK) inhibitors for cancer originally acquired from the Scripps Research Institute. Subsequently, the firm appears simply to have closed its doors.
